Resveratrol supplementation: Where are we now and where should we go? - PubMed (original) (raw)

Review

Resveratrol supplementation: Where are we now and where should we go?

Marta G Novelle et al. Ageing Res Rev. 2015 May.

Abstract

Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.

Keywords: Bioavailability; Clinical trials; Metabolism; Resveratrol; Translational research.

Published by Elsevier B.V.

PubMed Disclaimer

Figures

Figure 1

Summary of the effects of resveratrol in human clinical trials when conducted in patients with type 2 diabetes, obesity, cardiovascular disease, cancer or skin disorders. The symbol ⬌ denotes lack of effect, and ⬆⬇ opposite action in some trials.

Similar articles

• Significance of Resveratrol in Clinical Management of Chronic Diseases.
  Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J. Wahab A, et al. Molecules. 2017 Aug 18;22(8):1329. doi: 10.3390/molecules22081329. Molecules. 2017. PMID: 28820474 Free PMC article. Review.
• Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease.
  Csiszar A. Csiszar A. Ann N Y Acad Sci. 2011 Jan;1215:117-22. doi: 10.1111/j.1749-6632.2010.05848.x. Ann N Y Acad Sci. 2011. PMID: 21261649 Free PMC article. Review.
• Resveratrol and health--a comprehensive review of human clinical trials.
  Smoliga JM, Baur JA, Hausenblas HA. Smoliga JM, et al. Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: 10.1002/mnfr.201100143. Epub 2011 Jun 20. Mol Nutr Food Res. 2011. PMID: 21688389 Review.
• Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes.
  Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Poulsen MM, et al. Biochim Biophys Acta. 2015 Jun;1852(6):1124-36. doi: 10.1016/j.bbadis.2014.12.024. Epub 2015 Jan 9. Biochim Biophys Acta. 2015. PMID: 25583116 Review.
• Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-κB activation in Caco-2 and SW480 human colon cancer cells.
  Panaro MA, Carofiglio V, Acquafredda A, Cavallo P, Cianciulli A. Panaro MA, et al. Br J Nutr. 2012 Nov 14;108(9):1623-32. doi: 10.1017/S0007114511007227. Epub 2012 Jan 17. Br J Nutr. 2012. PMID: 22251620

Cited by

• Neurohormetic phytochemicals: An evolutionary-bioenergetic perspective.
  Murugaiyah V, Mattson MP. Murugaiyah V, et al. Neurochem Int. 2015 Oct;89:271-80. doi: 10.1016/j.neuint.2015.03.009. Epub 2015 Apr 7. Neurochem Int. 2015. PMID: 25861940 Free PMC article. Review.
• The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review.
  Atazadegan MA, Bagherniya M, Fakheran O, Sathyapalan T, Sahebkar A. Atazadegan MA, et al. Adv Exp Med Biol. 2021;1328:37-57. doi: 10.1007/978-3-030-73234-9_4. Adv Exp Med Biol. 2021. PMID: 34981470 Review.
• Resveratrol and Its Effects on the Vascular System.
  Breuss JM, Atanasov AG, Uhrin P. Breuss JM, et al. Int J Mol Sci. 2019 Mar 27;20(7):1523. doi: 10.3390/ijms20071523. Int J Mol Sci. 2019. PMID: 30934670 Free PMC article. Review.
• Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials.
  Li Q, Yang G, Xu H, Tang S, Lee WY. Li Q, et al. BMC Complement Med Ther. 2021 Aug 22;21(1):214. doi: 10.1186/s12906-021-03381-4. BMC Complement Med Ther. 2021. PMID: 34420523 Free PMC article.
• Acute oral treatment with resveratrol and Lactococcus Lactis Subsp. Lactis decrease body weight and improve liver proinflammatory markers in C57BL/6 mice.
  Mendes KL, Lelis DF, de Freitas DF, da Silveira LH, de Paula AMB, Guimarães ALS, Oliveira JR, Andrade MC, Nobre SAM, Santos SHS. Mendes KL, et al. Mol Biol Rep. 2021 Feb;48(2):1725-1734. doi: 10.1007/s11033-021-06190-7. Epub 2021 Feb 14. Mol Biol Rep. 2021. PMID: 33586053

References

1. 1. Adeghate E, Donath T, Adem A. Alzheimer disease and diabetes mellitus: do they have anything in common? Curr Alzheimer Res. 2013;10:609–617. - PubMed
2. 1. Adhami VM, Afaq F, Ahmad N. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia. 2003;5:74–82. - PMC - PubMed
3. 1. Afaq F, Adhami VM, Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol. 2003;186:28–37. - PubMed
4. 1. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, Baur JA, Smoliga JM. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013;166:246–248. - PMC - PubMed
5. 1. Alfaras I, Juan ME, Planas JM. trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J Agric Food Chem. 2010;58:8104–8110. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information